Although clinical applications of the CRISPR-Cas9 strategy in targeting the EWSR1::FLI1 fusion in Ewing’s sarcoma remain to be seen, there has been recent development of small molecule inhibitors to target the genetic fusion proteins of EWSR1::FLI1. This evidence concerns the gene EWSR1 and Ewing sarcoma.